GeoVax Publications

NPJ Vaccines, September 02, 2020.
Malherbe D, Domi A, Hauser MJ, Meyer M, Gunn BM, Alter G, Bukreyev A, Guirakhoo F
Pathogens, August 28, 2019.  
Salvato MS, Domi A, Guzman-Cardozo C, Medina-Moreno S, Zapata JC, Hsu H, McCurley N, Basu R, Hauser M, Hellerstein M, Guirakhoo F
Clinical Pharmacology & Therapeutics, August 12, 2018.
Robinson, HL 
Scientific Reports.  January 16, 2018.
Domi A, Feldmann F, Basu R, McCurley N, Shifflett K, Emanuel J, Hellerstein MS, Guirakhoo F, Orlandi C, Flinko R, Lewis GK, Hanley PW, Feldmann H, Robinson HL, Marzi A
Scientific Reports. November 07, 2017.
Brault AC, Domi A, McDonald EM, Talmi-Frank D, McCurley N, Basu R, Robinson HL, Hellerstein M, Duggal NK, Bowen RA, Guirakhoo F
PLOS ONE, October 11, 2017.
McCurley NP, Domi A, Basu R, Saunders KO, LaBranche CC, Montefiori DC, Haynes BF, Robinson HL
PLOS ONE, July 20, 2017.
Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM,
Goepfert PA, Baden LR, Robinson HL, Yu X,  Gilbert PB, McElrath MJ, Huang Y, Tomaras GD, HIV Vaccine Trials Network (HVTN) 094 Study Group.
Curr Opin Virol. 2016 Apr;17:viii-x. doi: 10.1016/j.coviro.2016.05.006.
Robinson HL, Mulligan MJ.
Open Forum Infect Dis.2016 Feb 11;3(1):ofw034. doi: 10.1093/ofid/ofw034. eCollection 2016.
Chamcha V, Kannanganat S, Gangadhara S, Nabi R, Kozlowski PA, Montefiori DC, LaBranche CC, Wrammert J, Keele BF, Balachandran H, Sahu S, Lifton M, Santra S, Basu R, Moss B, Robinson HL, Amara RR
Control of a mucosal challenge and prevention of AIDS in rhesus macaques by multiprotein DNA/MVA vaccine.
Science. 2001 Apr 6;292(5514):69-74.
Amara RR, Villinger F, Altman JD, Lydy SL, O'Neil SP, Staprans SI, Montefiori DC, Xu Y, Herndon JG, Wyatt LS, Candido MA, Kozyr NL, Earl PL, Smith JM, Ma H-L, Grimm BD, Hulsey ML, McClure HM, McNicholl JM, Moss B, and Robinson HL.

DNA vaccines, protective immunizations by parenteral, mucosal, and gene gun inoculations.
Proceedings of the National Academy of Sciences of the United States of America. 1993 Dec 15;90(24):11478-82.
Fynan EF, Webster RG, Fuller DH, Haynes JR, Santoro JC, and Robinson HL. CRITICAL STUDIES ON OUR PATH TO AN AIDS VACCINE

Preclinical studies of human immunodeficiency virus/AIDS vaccines: inverse correlation between avidity of anti-Env antibodies and peak postchallenge viremia.
Journal of Virology, 2009 May;83(9):4102-11. Epub 2009 Feb 18.
Zhao J, Lilin L, Montefiori, DC, Villinger F, Chennareddi L, Wyatt LS, Moss B and Robinson HL.

Signature for long-term vaccine-mediated control of a Simian and human immunodeficiency virus 89.6P challenge: stable low-breadth and low-frequency T cell response capable of coproducing gamma interferon and interleukin-2.
Journal of Virology 2005 Mar;79(6):3243-53.
Sadagopal S, Amara RR, Montefiori DC, Wyatt LS, Staprans SI, Kozyr NL, McClure HM, Moss B, Robinson HL.

Multiprotein HIV type 1 clade B DNA/MVA vaccine: construction, safety, and immunogenicity in Macaques.
AIDS Research and Human Retroviruses 2004 Jun;20(6):654-65.
Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL.

DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
AIDS Research and Human Retroviruses 2004 Dec;20(12):1335-47.Smith JM, Amara RR, Campbell D, Xu Y, Patel M, Sharma S, Butera ST, Ellenberger DL, Yi H, Chennareddi L, Herndon JG, Wyatt LS, Montefiori D, Moss B, McClure HM, Robnson HL.

gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: Higher pre challenge antibody but poorer control of a live viral challenge.
AIDS Research and Human Retroviruses 2003 Oct;19(10):891-900.
Buge SL, Ma H-L, Amara RR, Wyatt LS, Earl PL, Villinger F, Montefiori DC, Staprans SI, Xu Y, O'Neil SP, Herndon JG, Hill E, Moss B, Robinson HL, and McNicholl JM.

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine.
Journal of Virology 2002 Jun;76(12):6138-46.
Amara RR, Smith JM, Staprans SI, Montefiori DC, Montefiori DC, Altman JD, O'Neil SP, Kozyr NL, Xu Y, Wyatt LS, Earl PL, Herndon JG, McNicholl JM, Moss B, and Robinson HL.

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations.
Nature Medicine 1999 May;5(5):526-34.
Robinson HL, Montefiori DC, Johnson RP, Manson KH, Kalish ML, Lifson JD, Rizvi TA, Lu S, Hu S-L, Mazzara GP, Panicali DL, Herndon JG, Glickman R, Candido MA, Lydy SL, Wyand MS, and McClure HM.

Simian immunodeficiency virus DNA vaccine trial in macaques.
Journal of Virology 1996 Jun;70(6):3978-91.
Lu S-H, Arthos J, Montefiori DC, Yasutomi Y, Manson K, Mustafa F, Johnson E, Santoro JC, Wissink J, Mullins JI, Haynes JR, Letvin NL, Wyand M, and Robinson HL.


T cell vaccines for microbial infections.
Nature Medicine 2005 Apr;11(4 Suppl):S25-32.
Robinson HL and Amara RR.

New hope for an AIDS vaccine.
Nature Reviews Immunology 2002 Apr;2(4):239-50.
Robinson HL.

The scientific future of DNA for immunization.
A position paper for the American Academy of Microbiology. 1997.
Robinson HL, Ginsberg H, Liu M, Davis H, and Johnston S.
Register to receive email alerts for GeoVax press releases
Copyright © GeoVax 2022. All Rights Reserved.